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Summary of Top Contributions
Dr. McCord's career in research began with the discovery of SOD and has since been devoted to understanding the mechanisms and physiological roles of superoxide radicals and SOD. His work serves as the foundation and fundamental understanding of superoxide radicals in aerobic metabolism as well as its role in a variety of pathophysiologies, particularly inflammation and ischemia-reperfusion injury. Research orchestrated by McCord illustrates the double-edged sword of superoxide generation as both a highly destructive byproduct of aerobic metabolism and as an essential actor in the immune response.
Relevance of Findings to Human Health
Dr. McCord's research discovering and characterizing the physiological roles of SOD contributes to the foundation of modern medicine's understanding of immune response and ischemia-reperfusion injuries and has helped to improve current treatments and medical procedures.
Area of Interest in Redox Biology
When Dr. McCord began his research career as a graduate student under the direction of Dr. Irwin Fridovich, the Fridovich laboratory was interested in the reduction of cytochrome c caused by xanthine oxidase. This reaction was observed in the presence of oxygen, but not in anoxic environments and was thought to be mediated by an electron bridge formed when a superoxide radical (O 2 -) bound to xanthine oxidase (8) . As a new member of the laboratory, McCord was assigned a project measuring the physical binding between xanthine oxidase and carbonic anhydrase, a proposed inhibitor of xanthine oxidase. Although thought to be a simple project, experiment after experiment failed to show the predicted binding between the two proteins. McCord began to reevaluate the hypothesis under which he was operating and considered other possible mechanisms for the decreased reduction rate of cytochrome c. He considered the reduction of cytochrome c as two half reactions with the possibility of superoxide acting as a free molecule in a solution. Superoxide had long been recognized as a product in xanthine oxidase catalysis (8); however, it had never been investigated as a free reducing agent of cytochrome c. With adjusted experimental direction, McCord discovered that cytochrome c did not bind to xanthine oxidase, nor did any other suspected inhibitors. This disproved the theory that cytochrome c was reduced by the xanthine oxidase-oxygen bridge complex and suggested that the reducing agent was instead a free superoxide radical produced by xanthine
FIG. 1. The oxidation of xanthine to uric acid by xanthine oxidase produces superoxide (O 2
2 ), which can undergo three possible fates: 1) spontaneous dismutation; 2) reduction of cytochrome c; or 3) reaction with superoxide dismutase to create H 2 O 2 . To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars 184 SCHNELL AND ST. CLAIR oxidase (19) . The article describing these findings has been cited over 9000 times. If cytochrome c was not a substrate of xanthine oxidase, and therefore was not outcompeted for xanthine oxidase binding sites by carbonic anhydrase, what was inhibiting the reduction? McCord and Fridovich recognized that the inhibiting factor would have to eliminate superoxide from the solution through catalyzing a dismutation reaction. The observed dismutase activity was initially attributed to carbonic anhydrase and myoglobin (18) .
McCord set out to purify the SOD-containing enzyme from bovine erythrocytes and produced a vivid, blue-green colored copper-containing protein exhibiting a specific activity of 3300 units per milligram (19) . McCord and Fridovich identified this blue-green enzyme to be the same as the copper storage proteins, erythrocuprein, hemocuprein, cerebrocuprein, hepatocuprein, and cytocuprein. Upon recognizing these supposedly unconnected and enzymatically inactive proteins were, in fact, all the same enzyme and moreover highly active in the dismutation of superoxide, McCord and Fridovich coined the name superoxide dismutase (19) and defined its activity as shown in reaction 1 (see also reaction 2 in Fig. 1 ).
Description of Key Finding 1
SOD is essential to aerobic life
After isolating and identifying SOD, the next investigative step was to determine its physiological role on a grand scale through the examination of SOD activity in a variety of aerobic and anaerobic bacteria. Oxygen toxicity was previously thought to be a result of hydrogen peroxide accumulation and therefore managed by catalase. However, McCord showed that catalase could not predict aerotolerance with 100% fidelity (20) , suggesting the involvement of another actor in aerotolerance. McCord and coworkers examined catalase and SOD activity in 26 microorganisms and showed that SOD was active in all examined bacteria capable of aerobic metabolism. Aerotolerant anaerobes, preferential anaerobes capable of aerobic metabolism, contained no catalase activity, but did exhibit SOD activity similar to and even exceeding their aerobic counterparts. This experiment was crucial in understanding the role of SOD in reactive oxygen species management and aerobic life.
Further research from the Fridovich laboratory showed that the copper-containing SOD, formerly identified as the cuprein family of proteins, was not the only variety of SOD. Working with Bernard Keele, McCord was part of the research group that discovered a second type of SOD in Escherichia coli. Through ultracentrifugation and dialysis, Keele isolated 16 mg of a red-purple protein exhibiting 3800 units of SOD activity per mg (16) . Electron paramagnetic resonance spectroscopy and quantitative colorimetric analysis identified 1.6-1.8 atoms of manganese per molecule of enzyme, distinguishing it as a completely new variety of SOD. Structurally and evolutionarily unrelated to the cupric SOD discovered in 1969 (CuZnSOD, SOD1), this manganese superoxide dismutase (MnSOD, SOD2) showed convergent evolution of SOD, emphasizing the necessity of SOD in a variety of biological systems. In his first article as an independent researcher, Dr. McCord established the role of superoxide in the deterioration of synovial fluid through a mechanism of free radical induced depolymerization (21) . He showed that this oxidative depolymerization of hyaluronic acid could be inhibited by either SOD or catalase, suggesting that the oxidative species responsible was neither superoxide nor hydrogen peroxide alone, but a product of a reaction between the two: the
FIG. 2. Granger and
McCord's proposed model for superoxide production in the ischemic bowel. As ischemia progresses, ATP is catabolized to AMP and further to hypoxanthine, a substrate of xanthine oxidase. In the hypoxic environment, xanthine oxidase is unable to oxidize hypoxanthine to xanthine and hypoxanthine concentrations within the cell increase. Upon reoxygenation of oxygen, xanthine oxidase is again able to oxidize hypoxanthine, which is available at very high concentrations. The rapid oxygenation of hypoxanthine produces superoxide faster than it can be scavenged by superoxide dismutase causing an increase in cellular-free superoxide and oxidative damage. AMP, adenosine monophosphate; ATP, adenosine triphosphate.
hydroxyl radical (OH$), a product of the Haber-Weiss reaction as depicted in reaction 2.
However, while the stoichiometry was accurate and the reaction is thermodynamically favorable, several studies (13, 17, 26) showed that the Haber-Weiss reaction did not occur naturally at any significant rate. In response to this, McCord separated the reaction into halves, investigating the possibility of chelated iron compounds as intermediaries (22) . The enzyme kinetics showed a competitive relationship between SOD and Fe 3 + -EDTA for the removal of superoxide, supporting McCord's theory of chelated iron intermediates to hydroxyl radical formation as shown in the reactions 3 and 4.
Description of Key Finding 3
A new look at ischemia reperfusion By the late 1970s, it was clear that superoxide had both deleterious and beneficial roles in multiple physiological systems. The superoxide radical had been implicated in oxygen toxicity resulting from normal oxidative metabolism (18) , necessitating obligatory expression of SOD by aerobic and aerotolerant organisms to manage oxidative damage (20) . It was also produced in large amounts through an oxidative burst during phagocytosis by neutrophils, monocytes, and macrophages as an essential component of the immune response (2) . Individuals lacking NADPH oxidase, the enzyme that creates the superoxide radicals in phagocytes, exhibit chronic granulomatous disease and are extremely susceptible to infection (6), often succumbing to fatal infections at a very young age.
Around the time of SOD's discovery, xanthine oxidase was strongly connected to hemorrhagic shock (5) and ischemic damage (7) . Knowing xanthine oxidase's role in producing oxygen radicals, McCord examined the role of superoxide in ischemia in the feline bowel as part of a team from the University of South Alabama led by Neil Granger. Their work showed that treatment with SOD before reperfusion of a 60-min ischemic insult prevented ischemia-induced increase in capillary permeability (11) . They hypothesized that during ischemia, adenosine triphosphate (ATP) was reduced to adenosine monophosphate (AMP), which was further catabolized to hypoxanthine. Upon tissue reoxygenation, xanthine oxidase rapidly converted hypoxanthine to xanthine, generating large quantities of superoxide. This model recognized that tissue damage was not caused by the lack of oxygen, but instead by free radical production during reperfusion, fundamentally changing medicine's understanding of ischemiareperfusion injury and treatment (Fig. 2) (10) .
Other Achievements
During research examining the production of superoxide by leukocytes and neutrophils, McCord recognized that 
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superoxide acts as an initiator of immune cell chemotaxis (23) . Building on this discovery, McCord's laboratory showed that administration of SOD before an inflammatory challenge through injection of xanthine oxidase (a superoxide generator) could preclude up to 99% of neutrophil recruitment, while treatment with catalase could only prevent 28% of neutrophil recruitment (25) . This model of superoxide-initiated chemotaxis (outlined in Fig. 3 ) represented a breakthrough in the understanding of superoxide and perhaps the first instance in which superoxide was demonstrated as a cellular signaling molecule.
McCord has also made major contributions to the understanding of reactive oxygen species and SOD in the immune system. His work has shown localized superoxide production in polymorphonuclear leukocytes as a bacteriocidal mechanism (27) and the use of SOD as a protective measure in phagocytosing leukocytes (28) . He was also a contributor to groundbreaking work implicating superoxide in myocardial damage from ischemia reperfusion (3, 4) in a fashion similar to that seen in intestinal ischemia. Expanding on this work, McCord showed that xanthine oxidase inhibitors are capable of preventing oxidative damage in both myocardial and intestinal ischemia-reperfusion injuries (4, 12) .
Beginning even before the discovery of its enzyme activity, a great deal of time and money has been spent in trying to make SOD into a clinically useful therapeutic agent to protect against inflammation, reperfusion injury, and oxidative damage. However, none of these attempts have achieved clinical success. In 2003, McCord and colleagues synthesized a chimeric SOD combining the body of SOD1 with the heparinbinding domain of SOD3 with improved pharmacological properties (9, 14) . However, a much more efficient and practical method of increasing human in situ antioxidant activity was recognized through the activation of nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor referred to as the ''master regulator of antioxidant enzymes.'' Nrf2 regulates the expression of not only SOD, also catalase, glutathione peroxidases, and many other enzymes active in the prevention and cleanup of oxidative damage. In recent years, McCord has developed a composition of five highly synergistic natural Nrf2 activators as a dietary supplement called ''Protandim Ò '' (15, 24, 29) .
Current Position
Dr. McCord has held faculty positions at Duke University, the University of South Alabama, and the University of Colorado. He served as the Chairman of the biochemistry department at the University of South Alabama for 9 years before relocating to the Webb-Waring Institute at the University of Colorado Anschutz Medical Campus in 1990 as the head of the Division of Biochemistry and Molecular Biology. As a Professor of Medicine at the University of Colorado, McCord held joint appointments in Biochemistry, Microbiology, and Toxicology until his retirement in 2011. Dr. McCord currently maintains an appointment as Clinical Professor of Medicine at the University of Colorado and serves as Chief Science Officer of LifeVantage Corp., which produces the Nrf2-activating dietary supplement Protandim. According to Prof. Joe McCord, ''My advice to students is this: Science requires the same creativity, inventiveness, and passion that we expect from artists, composers, and writers. When you feel it, you know it. If you don't feel it, then science probably isn't the best career choice for you. This has little to do with whether science seems easy or difficult. It always seemed difficult to me as a student, as it probably should.''
